

# Yves Allory

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4505287/publications.pdf>

Version: 2024-02-01

16  
papers

1,311  
citations

932766

10  
h-index

887659

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1980  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 12.e1-12.e11.	0.8	6
2	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	0.8	22
3	Overexpression of Nucleolin and Associated Genes in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4491.	1.8	7
4	Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. <i>European Urology</i> , 2021, 79, 214-221.	0.9	130
5	Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 148, 181-189.	1.3	70
6	Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7890-7900.	1.6	7
7	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	0.9	741
8	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 295-303.e3.	0.9	12
9	Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. <i>Environment International</i> , 2020, 135, 105346.	4.8	25
10	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? <i>European Urology</i> , 2020, 78, 682-687.	0.9	57
11	Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100536.	0.5	13
12	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. <i>Eur Urol</i> 2020;77:434-5. <i>European Urology</i> , 2020, 77, 436-438.	0.9	1
13	PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer. <i>Oncology Letters</i> , 2019, 18, 3471-3480.	0.8	10
14	Progenitors from the central nervous system drive neurogenesis in cancer. <i>Nature</i> , 2019, 569, 672-678.	13.7	188
15	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. <i>European Journal of Cancer</i> , 2019, 108, 111-119.	1.3	16
16	Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization. <i>Translational Andrology and Urology</i> , 2018, 7, 757-759.	0.6	4